PDCD1 and non-small cell lung carcinoma: Further markers such as AXL, HER2, HER3, MERTK, VIM, and RAD18 or error-prone polymerases could be examined in further clinical trials evaluating resistance or compensatory pathways and how they are affected by the combinational PD-1/PD-L1 and add-on VA therapy in advanced or metastasised NSCLC patients.